https://akt-signal.com/index.p....hp/inter-reviewer-va
Clinical outcome prediction and treatment selection strategies can benefit from registration-based biomarkers, which may help to surpass the visual limitations of radiographic evaluation. Ill-defined pancreatic ductal adenocarcinoma (PDAC) tumors may have their neoadjuvant treatment response differentiated via imaging biomarkers derived from longitudinal deformable image registration, which assesses volumetric changes. Improvi
Like
Comment
Share
